Relay Therapeutics, Inc. 4

Relay Therapeutics President and CEO Sanjiv Patel acquired 3,056 shares via ESPP and sold 48,199 common shares under a Rule 10b5-1 plan.

On June 30, 2026, President and CEO Sanjiv Patel voluntarily reported acquiring 3,056 shares of Relay Therapeutics, Inc. common stock under the company’s 2020 Employee Stock Purchase Plan at an ESPP price of $6.95 per share (approximately $21,000 in value), a transaction exempt under Rule 16b-3 and based on 85% of the January 2, 2026 closing price. On July 7, 2026, pursuant to a pre-established Rule 10b5-1 trading plan, he sold 48,199 shares of common stock at a weighted average price of $19.58 per share (approximately $943,000 in proceeds) in multiple trades executed between $18.52 and $20.20, reducing his direct holdings from 664,097 to 615,898 shares. In addition, the Form 4 notes indirect ownership of 199,548 and 687,355 shares held in separate irrevocable family trusts for which Patel disclaims beneficial ownership, and an independent trustee acts as trustee.

Filing Facts

CIK

1812364

Ticker

RLAY

Form

4

Source Type

fda

Accession

0001193125-26-298681

Alert Tier

6